178693-27-1

Usage

Uses

Used in Pharmaceutical Industry:
Telmisartan is utilized as an antihypertensive agent for the treatment of high blood pressure. It is used to relax blood vessels, which in turn lowers blood pressure and improves blood flow, reducing the risk of stroke, heart attack, and other cardiovascular complications.
Used in Cardiovascular Disease Management:
In the field of cardiovascular disease management, Telmisartan is employed as a therapeutic agent to mitigate the risk of stroke, heart attack, and other related complications in patients with hypertension. Its role in relaxing blood vessels aids in the overall improvement of cardiovascular health.
Used in Diabetes Treatment:
Telmisartan has shown potential as a treatment for diabetes, where it may help in managing blood sugar levels and reducing the risk of diabetes-related complications. Its use in this context is still under investigation, but it holds promise for future applications in diabetes management.
Used in Research and Development:
In the research and development sector, Telmisartan is studied for its potential applications in treating other conditions beyond hypertension and cardiovascular disease. Its chemical properties and mechanism of action are of interest to scientists exploring new therapeutic avenues for various health issues.

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 98-09-9 benzenesulfonyl chloride 
• 6232-11-7 methyl 4-(aminomethyl)benzoate hydrochloride 
• 471925-05-0 methyl 4-(phenylsulfonamidomethyl)benzoate 

Downstream Products

• 591217-95-7 4-(benzenesulfonylamino-methyl)-N-benzyloxy-benzamide 

Relevant academic research and scientific papers

Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201

GluN2A subunit containing N-methyl-D-aspartate receptors (NMDARs) are highly involved in various physiological processes in the central nervous system, but also in some diseases, such as anxiety, depression and schizophrenia. However, the role of GluN2A subunit containing NMDARs in pathological processes is not exactly elucidated. In order to obtain potent and selective inhibitors of GluN2A subunit containing NMDARs, the selective negative allosteric modulator 2 was systematically modified at the benzenesulfonamide part. The activity of the test compounds was recorded in two electrode voltage clamp experiments using Xenopus laevis oocytes expressing exclusively NMDARs with GluN1a and GluN2A subunits. It was found that halogen atoms in 3-position of the benzenesulfonamide part result in high GluN2A antagonistic activity. With an IC50 value of 204?nM the 3-bromo derivative 5i (N-{4-[(2-benzoylhydrazino)carbonyl]benzyl}-3-bromobenzenesulfonamide) has 2.5-fold higher antagonistic activity than the lead compound 2 and represents our new lead compound.

Heteroarylacetic phenylbenzamide, composition and method of use (by machine translation)

Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.

Solvent hydrogen bonding and structural effects on nucleophilic substitution reactions. Part-7: Reaction of benzenesulphonyl chloride with substituted benzylamines in acetonitrile/dimethylsulfoxide mixtures

Substitution reactions of eleven para- and meta-substituted benzylamines with benzenesulphonyl chloride in different mole fractions of dimethylsulfoxide (DMSO) in acetonitrile (AcN) have been investigated conductometrically. The second order rate constants found to increase with an increase in the mole fraction of DMSO up to 0.5 mole fraction and beyond that it remained nearly constant. Multiple correlation analysis of the rate data via Kamlet-Taft's solvatochromic parameters revealed that the solvent H-bonding and dipolarity/polarizability plays a dominant role in governing the reactivity and also solvent-solvent interaction influenced the preferential solvation and consequently the rate of the reaction. A curved Hammett plot was obtained and a mechanism was proposed to account for this nonlinear behaviour observed.

ABCA1 ELEVATING COMPOUNDS

The present invention provides compounds having the structure of Formula (I), wherein R1 is optionally substituted lower alkyl, optionally substituted cycloaikyl, or optionally substituted aryl; R2 is hydrogen, carboxyalkyl, optional

Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group

Utilizing tranexamic acid as a starting material, a series of N-hydroxycarboxamides were synthesized in order to seek new histone deacetylase (HDAC) inhibitors. Further structure optimization involving the replacement of the 1,4-cyclohexylene group with t